I put together an infographic to summarize several upcoming obesity medications currently in late-stage development, along with their mechanisms, estimated timelines, and approximate weight loss efficacy based on the most recent clinical trial data
The deterioration of barrier function, dysregulation of microecology, and amplification of pathogenic bacteria may lead to an increase in the levels of pro-atherosclerotic metabolites such as LPS and TMAO 131
consult a professional if concerns arise, and consider cycling off after ~8 weeks
Dng c cho tt c mi ngi k c ph n c thai
While OXPHOS produces sufficient ATP to support cellular functions, it also generates ROS as byproducts
They are best equipped to weigh the potential benefits against the risks, considering an individuals complete medical history, existing conditions, and other medications